


# MRI FUSION / USG PROSTATE REPORT


Consulting Pathologist: Test Pathologist, MD

PATIENT DEMOGRAPHICS					
PATIENT INFORMATION:	PHYSICIAN INFORMATION:	SPECIMEN INFORMATION:			
Patient, Test	Test Physician	ACCESSION #: TS22-00522			
DOB: 1/1/1954	Test Practice	PROCEDURE DATE: 3/6/2022			
Gender/Age: M/68	300 Columbus Circle, Suite A, Edison, NJ 08837	DATE RECEIVED: 3/7/2022			
SS#: UN:508410083	866.909.PATH, Fax:908-272-1478	REPORTED ON: 3/8/2022			

# **CLINICAL INFORMATION**

PSA Level = 5.3 ng/mL Clinical Stage: T2c, ICD-10: C61





DIAGNOSIS SUMMARY (USG BIOPSIES)					
Specimen	Diagnosis	CGS*	GG**	PTI	
A	Malignant	7(3+4)	2	25%	
E	ASAP				
*CCC. Commonite Classon Soons **Crade Crayer					

DIAGNOSIS SUMMARY (MRI FUSION BIOPSIES)					
Specimen	Diagnosis	CGS*	GG**	PTI	
K	Malignant	6(3+3)	1	20%	
*CGS: Composite Gleason Score, **Grade Group					

\*CGS: Composite Gleason Score, \*\*Grade Group

## FINAL DIAGNOSIS (USG BIOPSIES)

A: Left Apex: Adenocarcinoma of prostate. Gleason Score: 7(3+4). Gleason Score 4 is 25%. Involving 25% of total surface area and 1 of 1 core. Perineural Invasion not seen.

Core#	Gleason Score	Grade Group	Tumor Length (cm)	Core Length (cm)	%
1	7(3+4)	Grade Group 2	0.5	2.0	25

E: Left Base: Focus of atypical glands suspicious for malignancy.

B: Left Lateral Apex: Benign prostatic tissue.

C: Left Mid: Benign prostatic tissue.

D: Left Lateral Mid: Benign prostatic tissue.

Physician: Test Physician

Electronically signed out by: Test Pathologist, MD

Fax: 908-272-1478

300 Columbus Circle, Suite A, Edison, NJ 08837

Tel: 1-866-909-PATH

F: Left Lateral Base: Benign prostatic tissue.

G: Right Mid: Benign prostatic tissue.

H: Right Lateral Mid: Benign prostatic tissue.

I: Right Base: Benign prostatic tissue.

J: Right Lateral Base: Benign prostatic tissue.

#### FINAL DIAGNOSIS (MRI FUSION BIOPSIES)

K: Right Apex, MRI/TRUS Fusion: Adenocarcinoma of Prostate. Composite Gleason Score: 6(3+3). Involving 20% of total surface area, and 2 of 2 cores. Perineural invasion not seen.

Core#	Gleason Score	Grade Group	Tumor Length (cm)	Core Length (cm)	%
1	6(3+3)	1	0.3	1.5	20
2	6(3+3)	1	0.4	2.0	20

### **COMMENTS**

Specific immunostains CK34\(\textit{BE}\)12 and P504S (AMACR) were performed on specimens A, E and M and the results support the above diagnosis in the presence of adequate controls.


These tests were validated and their performance characteristics determined by QDx Pathology Services. They may not be cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes.


The new five-tiered prostate Grade Group system, as adopted by WHO, is defined such that each group is associated with a unique prognosis based on PSA biochemical recurrence as an endpoint.

- Grade Group 1: Gleason Score < /= 6
- Grade Group 2: Gleason Score 7(3+4)
- Grade Group 3: Gleason Score 7(4+3)
- Grade Group 4: Gleason Score 8
- Grade Group 5: Gleason Scores 9-10

In a large (>3500 patients) single institutional study, the 5-year actuarial biochemical recurrence-free survival for biopsy Grade Groups 1-5 were 94.2%, 89.2%, 73.1%, 63.1%, and 54.7%, in patients treated with radical prostatectomy.

Ref: A contemporary prostate cancer grading system: a validated alternative to the Gleason Score. Eur Urol. 2016;69(3):428-35. Independent surgical validation of the new prostate cancer Grade-Grouping system. BJU Int. 2016;118(5):763-769.





\* Partin Table Reference: James Buchanan Brady Urological Institute, Johns Hopkins Medicine (http://urology.jhu.edu/prostate/partintables.php)

cap

Tel: 1-866-909-PATH